264 related articles for article (PubMed ID: 1643692)
1. Do anticancer agents reach the tumor target in the human brain?
Donelli MG; Zucchetti M; D'Incalci M
Cancer Chemother Pharmacol; 1992; 30(4):251-60. PubMed ID: 1643692
[TBL] [Abstract][Full Text] [Related]
2. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.
Stewart DJ
J Neurooncol; 1994; 20(2):121-39. PubMed ID: 7807190
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic considerations in the treatment of CNS tumours.
Motl S; Zhuang Y; Waters CM; Stewart CF
Clin Pharmacokinet; 2006; 45(9):871-903. PubMed ID: 16928151
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients.
Guntner AS; Peyrl A; Mayr L; Englinger B; Berger W; Slavc I; Buchberger W; Gojo J
Acta Neuropathol Commun; 2020 Jun; 8(1):78. PubMed ID: 32493453
[TBL] [Abstract][Full Text] [Related]
5. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J; Agrahari V; Youm I
J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
Muldoon LL; Soussain C; Jahnke K; Johanson C; Siegal T; Smith QR; Hall WA; Hynynen K; Senter PD; Peereboom DM; Neuwelt EA
J Clin Oncol; 2007 Jun; 25(16):2295-305. PubMed ID: 17538176
[TBL] [Abstract][Full Text] [Related]
7. Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.
Ginsberg S; Kirshner J; Reich S; Panasci L; Finkelstein T; Fandrich S; Fitzpatrick A; Shechtman L; Comis R
Cancer Treat Rep; 1981; 65(5-6):477-83. PubMed ID: 6165472
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.
Mellett LB
Cancer Treat Rep; 1977 Jul; 61(4):527-31. PubMed ID: 884690
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.
Jacus MO; Daryani VM; Harstead KE; Patel YT; Throm SL; Stewart CF
Clin Pharmacokinet; 2016 Mar; 55(3):297-311. PubMed ID: 26293618
[TBL] [Abstract][Full Text] [Related]
10. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
[TBL] [Abstract][Full Text] [Related]
11. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.
Chamberlain MC
Expert Rev Neurother; 2010 Apr; 10(4):547-61. PubMed ID: 20367207
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of brain tumors].
Kuratsu J; Ushio Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():377-83. PubMed ID: 7986118
[TBL] [Abstract][Full Text] [Related]
13. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
Deeken JF; Löscher W
Clin Cancer Res; 2007 Mar; 13(6):1663-74. PubMed ID: 17363519
[TBL] [Abstract][Full Text] [Related]
14. BBB penetration-targeting physicochemical lead selection: Ecdysteroids as chemo-sensitizers against CNS tumors.
Müller J; Martins A; Csábi J; Fenyvesi F; Könczöl Á; Hunyadi A; Balogh GT
Eur J Pharm Sci; 2017 Jan; 96():571-577. PubMed ID: 27810561
[TBL] [Abstract][Full Text] [Related]
15. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
16. [The blood-brain barrier: implications for chemotherapy in brain tumors].
Boaziz C; Breau JL; Morère JF; Israël L
Pathol Biol (Paris); 1991 Oct; 39(8):789-95. PubMed ID: 1762838
[TBL] [Abstract][Full Text] [Related]
17. Human central nervous system pharmacology of pentamethylmelamine and its metabolites.
Stewart DJ; Benvenuto JA; Leavens M; Smith RG; Cabanillas F; Benjamin RS; Loo TL
J Neurooncol; 1983; 1(4):357-64. PubMed ID: 6432969
[TBL] [Abstract][Full Text] [Related]
18. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.
Serwer LP; James CD
Adv Drug Deliv Rev; 2012 May; 64(7):590-7. PubMed ID: 22306489
[TBL] [Abstract][Full Text] [Related]
19. Transporter-based delivery of anticancer drugs to the brain: improving brain penetration by minimizing drug efflux at the blood-brain barrier.
On NH; Miller DW
Curr Pharm Des; 2014; 20(10):1499-509. PubMed ID: 23789953
[TBL] [Abstract][Full Text] [Related]
20. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
Sarin H
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
